產品屬性：
產品名稱 | Propentofylline |
規格 | 5mg、10mg、25mg、50mg |
貨號 | EY-01Y13813 |
Cas No.: 55242-55-2
別名: N/A
化學名: N/A
分子式: C15H22N4O3
分子量: 306.4
溶解度: Acetonitrile: slightly soluble,Chloroform: slightly soluble
儲存條件: Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產品描述：
Propentofylline is a xanthine derivative and neuroprotective agent.1,2 It increases NGF production in primary mouse astroglia when used at concentrations ranging from 0.12 to 3.33 mM, with the maximum increase observed at 1.11 mM.1 Propentofylline (20 μg/ml) reduces cell death induced by amyloid-β (1-42) in primary rat hippocampal neurons.2 Intravenous infusion of propentofylline (0.01, 0.05, and 0.1 mg/kg per minute) reduces infarct volume in a rat model of ischemic brain damage induced by permanent middle cerebral artery occlusion (MCAO) when administered following MCAO.3 It inhibits cAMP phosphodiesterases, is an antagonist of adenosine A1 and A2 receptors, and binds to adenosine transporters.4,5|1. Shinoda, I., Furukawa, Y., and Furukawa, S. Stimulation of nerve growth factor synthesis/secretion by propentofylline in cultured mouse astroglial cells. Biochem. Pharmacol. 39(11), 1813-1816 (1990).|2. Koriyama, Y., Chiba, K., and Mohri, T. Propentofylline protects β-amyloid protein-induced apoptosis in cultured rat hippocampal neurons. Eur. J. Pharmacol. 458(3), 235-241 (2003).|3. Park, C.K., and Rudolphi, K.A. Antiischemic effects of propentofylline (HWA 285) against focal cerebral infarction in rats. Neurosci. Lett. 178(2), 235-238 (1994).|4. Nagata, K., Ogawa, T., Omosu, M., et al. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity. Arzneimittelforschung 35(7), 1034-1036 (1985).|5. Fredholm, B.B., Fastbom, J., Kvanta, A., et al. Further evidence that propentofylline (HWA 285) influences both adenosine receptors and adenosine transport. Fundam. Clin. Pharmacol. 6(3), 99-111 (1992).
特別提醒公司產品僅供科研使用
